Posts by Immunexpress
Sepsis: the largely unknown condition that puts one million people in the hospital each year
Sepsis is the most expensive cause of hospitalization in the US. One million patients are hospitalized for sepsis each year. This is more than the number of hospitalizations for heart attack and stroke combined. And it is deadly. Despite these grave consequences, fewer than half of Americans know what the word sepsis means. By Hallie Prescott and Theodore Iwashyna.
Read MoreAvoidable Sepsis Infections Send Thousands Of Seniors To Gruesome Deaths
No one tracks sepsis cases closely enough to know how often these severe infections turn fatal. But the toll — both human and financial — is enormous, finds an investigation by KHN and the Chicago Tribune. By Fred Schulte and Elizabeth Lucas and Joe Mahr, Chicago Tribune.
Read MoreMost People Don’t Know What Sepsis Is
September is Sepsis Awareness Month and part of the problem in fighting sepsis is that most people don’t know what it is, reports Westwood One. However, now there may be a faster way to detect it. Sepsis occurs when the body’s efforts to fight an infection trigger inflammation throughout the body. CEO of Immunexpress Rollie…
Read MoreEuropean and U.S. Patent Allowances Strengthen Immunexpress’ Leading Position in Host-Response Sepsis Diagnostics
Patent Allowances Relate to SeptiCyte™ Technology Using Biomarkers These allowances further reinforce the claims of the core family of patents that support the Company’s gene expression technology in the detection of host response to sepsis SEATTLE, Sept. 24, 2018 – Immunexpress, Inc., today announced the receipt of ‘Notices of Allowance’ from both the U.S. Patent…
Read MoreMolecular Laboratory Test Can Discriminate Sepsis From Noninfectious SIRS
Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine.
Read MorePeople in the News: Rolland Carlson, Tanja Dowe, Katleen Verleysen
Accomplished industry leaders join recently appointed CEO, Dr. Rolland Carlson, to expand on the comprehensive experience of the Board.
Read MoreImmunexpress Saving Lives with Improved Sepsis Diagnosis: Interview with Rolland Carlson PhD, CEO
Medgadget editor Tom Peach sat down with Dr.Carlson from Immunexpress to hear more about the company’s first FDA-approved sepsis diagnostic test, SeptiCyte, and what the future of sepsis diagnosis and treatment may look like.
Read More3 Need-to-Know Leaps in Sepsis Care
Rolland Carlson, PhD, CEO of Immunexpress, discusses a different approach to the sepsis battle. Rather than passively chasing pathogens, the Company has developed a test to measure the body’s specific immune response to infection by examining biomarkers in the patient’s blood.
Read MoreImmunexpress is proud to be one of the sponsors for the 2nd World Sepsis Conference, Sept 5-6, 2018
“The 2nd World Sepsis Congress will be held on September 5th and 6th, 2018 – free of charge and completely online, so you can participate from wherever you have an internet connection. Over the course of 17 sessions, more than 100 speakers from 30 countries will discuss all aspects of sepsis and its wide-ranging consequences.…
Read MoreImmunexpress is a finalist for the 2018 MedTech Best Proof-of-Value of an Innovation award
“LONDON – AUGUST 13, 2018 – Informa Pharma Intelligence today announces the finalists for the 2018 Medtech Insight Awards. The diverse group of finalists were chosen by a highly respected independent panel of experts from across the sector.” — Pharma Intelligence https://pharmaintelligence.informa.com/events/awards/medtech-insight-awards-2018
Read More